SELECT Framework Predicts Cancer Therapy Response via Transcriptome
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current approaches in precision oncology lack systematic methods to utilize tumor transcriptomics data effectively for predicting cancer therapy responses, relying on heuristic exploratory methods that fail to generalize across various cancer types and treatments.
Innovation Solution
The SELECT framework identifies synthetic lethality (SL) and synthetic rescue (SR) genetic interactions by analyzing omics data and phylogenetic profiles to predict cancer therapy responses, using a computational pipeline that filters and ranks candidate gene partners based on their expression levels and interaction significance, thereby selecting personalized cancer therapies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If heuristic exploratory methods are used to predict cancer therapy responses, then the approach is simple to implement, but the prediction accuracy and generalizability across cancer types are insufficient
Solution Approach 1:
The system segments the complex task of therapy response prediction into distinct functional modules: data acquisition module, data processing module, genetic interaction analysis module, and therapy recommendation module. Each module handles specific aspects of the analysis, improving overall prediction accuracy while maintaining manageable system complexity through modular design.
Solution Approach 2:
The system introduces computational algorithms and genetic interaction networks as intermediaries between raw omics data and therapy response predictions. These intermediaries process and transform the data through systematic analysis of synthetic lethality and synthetic rescue interactions, enhancing prediction accuracy without requiring direct complex heuristics.
2Reliability
If comprehensive omics data and phylogenetic profiles are analyzed to identify synthetic lethality and synthetic rescue interactions, then the therapy prediction becomes more accurate, but the computational complexity and data processing requirements increase
Solution Approach 1:
The system performs preliminary processing of omics data and phylogenetic profiles before main analysis, including data normalization, quality control, and pre-computation of genetic interaction networks. This preliminary action reduces the complexity of subsequent analysis while maintaining reliable therapy predictions by ensuring data readiness and reducing computational burden during critical prediction phases.
Solution Approach 2:
The system applies different processing strategies and analysis methods to different types of data and different cancer types based on their specific characteristics. For example, specific genetic interaction networks are constructed for targeted therapy versus immunotherapy predictions, and data processing parameters are optimized for each cancer type, improving reliability without uniformly increasing complexity across all cases.
3Measurement precision
If the system filters and ranks candidate gene partners based on expression levels and interaction significance, then the identification of predictive biomarkers becomes more precise, but the processing time and computational resources increase
Solution Approach 1:
The system implements multi-level filtering strategies where initial broad filtering identifies candidate gene partners, followed by selective detailed analysis of top candidates. Not all candidate genes undergo complete analysis - only those passing initial filters are subjected to detailed expression level and interaction significance assessment, maintaining biomarker identification precision while reducing overall processing time through selective partial analysis.
Data Source
AI summary
The present disclosure relates to systems and methods for predicting response to cancer therapy, genes useful for predicting the sensitivity of a cancer to an anti-cancer therapy, and methods of treating such cancer.